Introduction: AZD9291 (osimertinib) is designed for acquired T790M mutation after first-and secondgeneration EGFR) tyrosine kinase inhibitors have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment.
Introduction
Approximately 5% to 10% of never-smoking white and 60% to 70% of never-smoking Asian patients with lung adenocarcinoma harbor an EGFR gene mutation and benefit from EGFR tyrosine kinase inhibitor (TKI) treatment. 1 Almost all of these patients eventually became resistant to EGFR TKIs. The most common mechanism of resistance to first-and second-generation EGFR TKIs (gefitinb, erlotinib, and afatinib) is emergence of the T790M mutation in exon 20, which causes a steric hindrance and increases the binding affinity of EGFR for adenosine triphosphate. The gatekeeper for T790M can be detected in 50% to 60% of biopsy samples after resistance has developed. 1 Osimertinib is a mutation-selective, third-generation irreversible EGFR TKI, and it has potency against tumors bearing EGFR activating mutations (L858R or exon 19 deletion) in the presence of a T790M mutation. An extended phase I study (AURA) and phase II study (AURA 2) of osimertinib demonstrated an objective response rate of 61% in patients with T790M mutations. 2 The U.S. Food and Drug Administration has granted accelerated approval to osimertinib.
However, after a median 10 months of treatment with osimertinib, drug resistance developed again. The most common mechanism is a newly acquired EGFR C797S mutation anticipated to induce resistance to all covalent EGFR TKIs. 3 Other resistance mechanisms include SCLC transformation, mitogen-activated protein kinase 1 gene (MAPK1)/AKT serine/threonine kinase 3 gene (AKT3) overexpression, fibroblast growth factor 2 gene (FGF2) overexpression, phosphatase and tensin homolog gene (PTEN) deletion, 4 and erb-b2 receptor tyrosine kinase 2 gene (HER2), and MNNG HOS Transforming gene (MET) amplification with loss of T790M. 5 Third-generation EGFR inhibitors are structurally distinct from first-and secondgeneration EGFR inhibitors. It would be useful to know whether acquired mechanisms of resistance to existing EGFR inhibitors other than T790M would also lead to cross-resistance to third-generation EGFR inhibitors. If not, blockade of both pathways might be an effective treatment strategy.
Methods

Cancer Cell Line Establishment
Malignant pleural effusion from this patient was collected by centrifugation, and excess red blood cells in cell pellets were removed by using a red blood cell lysis buffer. After washing and centrifugation, the partially purified cancer cells were cultured in F medium. 6 Cancer cells and other normal cells were separated by differential trypsinization during cell passage. After several passages, pure cancer cells were obtained and then adapted to Roswell Park Memorial Institute medium containing 10% fetal bovine serum.
Mutation Detected by MALDI-TOF MS
The detection of mutations was performed by matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) 7 in accordance with the user's manual for the MassARRAY system (Sequenom, San Diego, CA). The customized primers and probes used for analysis of the mutations have been described in a previous report. 8 
Western Blotting
Western blotting was performed as previously described. The primary antibodies used included p-EGFR (T1068), EGFR, p-AKT (S473), AKT, p-MEK1/2 (S217/ 221), MEK1/2, p-ERK1/2 (T202/Y204), and ERK1/2, all from Cell Signaling Technology (Danvers, MA), BRAF (Abcam [Cambridge, MA]), and a-tubulin (Genetex, Zeeland, MI). Secondary antibodies used included horseradish peroxidase-conjugated anti-mouse immunoglobulin G and horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (Genetex).
Anchorage-Dependent Colony Formation Assay
Cells (2 Â 10 4 cells per well) were seeded into 12-well plates in Roswell Park Memorial Institute medium containing 10% fetal bovine serum and grown separately from and in combination with the drugs (AZD9291 and LGX818) at the indicated concentrations for 7 days. At the end of the experiment, the cells were washed in phosphate-buffered saline, fixed in 4% paraformaldehyde, and stained with 0.1% crystal violet.
Results
In 2010 adenocarcinoma of the left lung was diagnosed in a 42-year-old man without a smoking history. He underwent palliative radiation to several bony sites of the disease (cT2N0M1b stage IV disease with multiple bone metastases). Tumor genotyping by direct sequencing revealed the presence of an exon 21 mutation (L858R) in his baseline biopsy sample; subsequent treatments included pemetrexed plus cisplatin, gefitinib, and erlotinib, followed by gemcitabine. His disease progressed in August 2014 with the development of new lung metastases. A biopsy of one of the new lung lesions was performed, and tumor genotyping with MALDI-TOF MS revealed T790M mutation and an exon 19 deletion. 7 He entered a phase I trial (NCT01802632) of AZD9291 (osimertinib) with a fixed dose of 80 mg in September 2014. He had a partial response, but malignant pleural effusion developed after a response duration of 13 months. Repeated tumor genotyping of the malignant effusion revealed a new BRAF V600E mutation in addition to the exon 19 deletion plus T790M. Confluent and attached cells grew from this effusion 3 months later (Fig. 1) . Genotyping of these primary culture cells by MALDI-TOF MS also showed the same mutation pattern of an exon 19 deletion plus T790M plus BRAF V600E (Fig. 1) . This cell is mainly dependent on the MEK ERK pathway because it has no AKT phosphorylation compared with H1975 (L858R plus T790M) (Fig. 2). LGX818 (encorafenib), a potent BRAF V600E inhibitor, could inhibit MEK phosphorylation in this cell, but it had no effect on H1975. Osimertinib can suppress EGFR phosphorylation without any effect on MEK and ERK in this cell, but it significantly inhibits AKT, MEK and ERK phosphorylation in osimertinib-sensitive H1975 cells. It is interesting that when encorafenib and osimertinib were combined, ERK phosphorylation could be further suppressed (see Fig. 2 ). Furthermore, encorafenib could suppress the colony formation of this cell (Fig. 3) at a low dose. Osimertinib had no ability to inhibit colony formation in a therapeutic range. However, combined encorafenib and osimertinib had a more potent inhibitory effect than encorafenib alone (see Fig. 3 ).
Discussion
We have described a patient with NSCLC and an exon 19 deletion plus T790M mutation who acquired resistance to osimertinib. Samples obtained at the time of progression showed a newly acquired mutation, BRAF V600E, in addition to the original mutation. At disease progression, malignant pleural effusion was collected from this patient and cultured. The cells revealed the same mutation. This cell was sensitive to the BRAF inhibitor encorafenib and resistant to osimertinib, but combined encorafenib and osimertinib was more potent than encorafenib alone.
An oncogenic driver of BRAF is found in approximately 2.6% to 3% of lung adenocarcinomas and V600E is found in approximately 50% of BRAF mutations. 9, 10 In our previous report, 0.7% of lung adenocarcinomas harbored a BRAF V600E mutation. 8 BRAF mutation rarely occurs in EGFR-mutant tumors. Patients with lung cancer who are harboring BRAF V600E are sensitive to BRAF inhibitors.
11
Resistance mechanisms to first-line EGFR TKIs other than T790M involve bypass pathways, including MET amplifications, HER2 amplifications, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutations, and BRAF mutations. 1, 12 One patient had a concurrent EGFR exon 19 deletion and EGFR T790M and BRAF V600E mutations after development of acquired resistance to first-line EGFR TKIs. 12 However, our patient acquired BRAF V600E after treatment with osimertinib. Although the BRAF V600E mutation is sensitive to BRAF inhibitors, there is no report in which BRAF inhibitors conferred acquired resistance after EGFR TKIs failed with a new BRAF V600E mutation.
This patient died 1 month after disease progression and did not receive a BRAF inhibitor. Cells cultured from this patient's effusion revealed the same mutation pattern. This osimertinib-resistant cell is RAS signaling pathway-dependent without AKT phosphorylation and is similar to WZ4002-resistant cells 12 ; it is sensitive to BRAF inhibitors. After encorafenib, MEK and phosphorylated MEK are suppressed and the ability for cell growth decreases. When encorafenib and osimertinib are combined, phosphorylated ERK decreases and cell growth is further suppressed. This combined blockade of the BRAF and EGFR at the same time had a significant inhibitory effect.
EGFR L858R was detected in this patient's baseline biopsy sample. After development of resistance to gefitinib and erlotinib, the repeat biopsy sample revealed an exon 19 deletion plus T790M. No L858R was detected, even after development of resistance to osimertinib. Different mutations have been shown to co-occur in a single tumor or in synchronous multiple tumors. 13, 14 After selection pressure by a potent EGFR TKI, a resistant clone might emerge from one of the complex mutations.
Cell lines derived from resistant patient samples are valuable tools for studying acquired resistance to TKIs in lung cancer. 15 This model is a better tool for the discovery and evaluation of therapeutic strategies for mechanisms of resistance in the real world than is using sensitive cell line models exposed to a specific targeted therapy until resistance emerges. LGX818 suppresses MEK signaling but had no significant effect on ERK phosphorylation. Combined LGX818 and AZD9291 had an effect on both MEK and ERK. H1975 cells harboring L858R plus T790M were used as a control. 
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